COMMUNIQUÉS West-GlobeNewswire

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
19/03/2026
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally [...]
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
19/03/2026
Company Announcement COPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 19, 2026, the Company’s Board of Directors met to constitute itself. Ms. [...]
Curia renforce ses capacités de production à Glasgow et consolide sa plateforme de développement de lignées cellulaires
19/03/2026
ALBANY, New York, 19 mars 2026 (GLOBE NEWSWIRE) -- Curia, acteur majeur de la recherche, du développement et de la fabrication sous contrat (CDMO), annonce ce jour la progression de l’extension de son site de production [...]
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
19/03/2026
Company announcement – No. 4 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 19, 2026 – Zealand Pharma A/S (“Zealand Pharma”) (NASDAQ: ZEAL [...]
Trading in GN Store Nord shares by board members, executives and associated persons
19/03/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
19/03/2026
– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan [...]
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
19/03/2026
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of Sales Foundation Established to Drive [...]
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
19/03/2026
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by [...]
electroCore Announces Full Year 2025 Financial Results and Organizational Changes
19/03/2026
Record f ull year 2025 net sales of $ 32.0 , an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales [...]
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
19/03/2026
Wegovy ® HD demonstrated a mean weight loss of 20.7% 1 , and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial First US FDA approval of a GLP-1 treatment under the Commissioner’s [...]
NMDP Celebrates Bipartisan Senate Introduction of Life-saving Blood Stem Cell Therapeutic and Research Reauthorization Act
19/03/2026
The C.W. Bill Young Cell Transplantation Program Has Impacted Nearly 150,000 Lives Since Inception, a 33% Increase in the Last Five Years MINNEAPOLIS, March 19, 2026 (GLOBE NEWSWIRE) -- NMDP SM , the nonprofit [...]
Backpage Sex Trafficking Survivors Break Silence, Demand Investigation of Uncharged Enablers as Compensation Deadline Approaches
19/03/2026
WASHINGTON, March 19, 2026 (GLOBE NEWSWIRE) -- With a March 31st court-imposed deadline approaching for Backpage sex trafficking victims to seek financial compensation, a group of approximately 20 survivors is publicly [...]
Fangzhou Reports Robust 2025 Financial Results, Boosted by AI Chronic Care Strategy
19/03/2026
SHANGHAI, March 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, reported its 2025 annual results, posting strong [...]
The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function
19/03/2026
The Endothelial Glycocalyx Is a Gel-Like Lining Inside Every Blood Vessel — and Most People Have Never Heard of It Standard Cardiovascular Screenings Focus on Large Arteries but Do Not Assess What Is Happening at the [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
19/03/2026
LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain [...]
SK pharmteco réaffirme sa stratégie à trois unités d’activité et renforce son pôle mondial de thérapie génique grâce à un engagement de financement
19/03/2026
RANCHO CORDOVA, Californie, 19 mars 2026 (GLOBE NEWSWIRE) -- SK pharmteco a annoncé aujourd’hui un engagement de financement significatif visant à soutenir des initiatives stratégiques au sein de son activité de [...]
New partnership to fast-track Canadian health technology from innovation to patient care
19/03/2026
AIM Institute and CAN Health Network join forces to help Canadian solutions reach clinicians and patients faster NEW WESTMINSTER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Royal Columbian Hospital Foundation’ [...]
BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health
19/03/2026
BrainsWay’s investment is part of its ongoing strategy to partner with leading U.S. mental health providers to increase access to care BURLINGTON, Mass. and JERUSALEM, March 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. ( [...]
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
19/03/2026
MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]

Pages